AbbVie (NYSE: ABBV) has long been a darling of dividend growth investors, and for good reason. Since its spinoff from Abbott ...

In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...

For years, the healthcare industry has been a cornerstone of the economy, offering resilience in both stable and uncertain ...

Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

To focus on its growing position in emerging markets, Abbott created the Established Pharmaceuticals Division in 2010. The creation of AbbVie In 2011, Abbott announced it was to separate into two ...

New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and ...